Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Xeris Biopharma Holdings, Inc. received a consensus rating of "Moderate Buy" from six analyst firms, with a twelve-month average target price of $6.58.
• Insider transactions included Kevin Mcculloch buying 25,000 shares at $4.38 each, while Director John Johnson sold 107,500 shares at an average price of $7.32.
• The company recently reported an EPS of ($0.01) for the last quarter, exceeding analyst estimates, with revenues of $67.71 million.

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $6.5833.

A number of analysts have recently commented on the company. Oppenheimer boosted their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Wall Street Zen raised Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Xeris Biopharma in a report on Tuesday, August 12th.

Insider Buying and Selling

In related news, insider Kevin Mcculloch bought 25,000 shares of the firm's stock in a transaction on Friday, June 13th. The stock was acquired at an average cost of $4.38 per share, for a total transaction of $109,500.00. Following the purchase, the insider owned 1,708,585 shares in the company, valued at approximately $7,483,602.30. This represents a 1.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Johnson sold 107,500 shares of the business's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $7.32, for a total transaction of $786,900.00. Following the sale, the director owned 833,483 shares of the company's stock, valued at approximately $6,101,095.56. This represents a 11.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.47% of the stock is owned by company insiders.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC raised its stake in Xeris Biopharma by 92.1% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 31,254 shares of the company's stock valued at $172,000 after buying an additional 14,986 shares during the last quarter. Millennium Management LLC grew its position in shares of Xeris Biopharma by 34.8% during the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock valued at $6,606,000 after acquiring an additional 502,853 shares during the period. Geode Capital Management LLC grew its position in shares of Xeris Biopharma by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company's stock valued at $11,364,000 after acquiring an additional 17,956 shares during the period. Two Sigma Advisers LP bought a new stake in shares of Xeris Biopharma during the 4th quarter valued at $47,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Xeris Biopharma during the 4th quarter valued at $45,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Stock Performance

Xeris Biopharma stock opened at $7.68 on Friday. The stock's 50 day simple moving average is $5.23 and its two-hundred day simple moving average is $4.72. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -36.57 and a beta of 0.65. Xeris Biopharma has a fifty-two week low of $2.48 and a fifty-two week high of $7.72.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $67.71 million during the quarter, compared to the consensus estimate of $64.58 million. On average, analysts predict that Xeris Biopharma will post -0.41 earnings per share for the current year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.